Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$8.90 USD
-0.29 (-3.16%)
Updated Nov 6, 2025 04:00 PM ET
After-Market: $8.92 +0.02 (0.22%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FOLD 8.90 -0.29(-3.16%)
Will FOLD be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for FOLD
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
Other News for FOLD
FOLD forms Upper Bollinger Band Walk on November 5
Amicus price target raised to $19 from $18 at JPMorgan
Amicus price target raised by $1 at JPMorgan, here's why
Bank of America Securities Sticks to Its Buy Rating for Amicus (FOLD)
JP Morgan Raises Price Target for Amicus Therapeutics (FOLD) to $19 | FOLD Stock News